News

Precision Biologics to present new data on NEO-201 at the Society for Immunotherapy of Cancer (SITC)

Strattmont Group2023-11-02T19:08:35-04:00

Precision Biologics presents new data from ongoing NEO-201 clinical trial at the Society for Immunotherapy...

Precision Biologics Announces new US Patent on its lead asset, NEO-201

Strattmont Group2023-10-05T20:43:57-04:00

Precision Biologics Announces the United States Patent and Trademark Office (USPTO) has granted a Patent...

Precision Biologics to give presentation at CICON 2023, Milan, Italy – shares new NEO-201 data from current Phase 2 Clinical Trial

Strattmont Group2023-09-19T14:31:28-04:00

Precision Biologics announces that Massimo Fantini PhD, our Director of Research and Development, will deliver...

AACR 2023 – Poster presentation in person, Orlando, FL, Orange County Convention Center, Tuesday, April 18th, 2023

Strattmont Group2023-04-17T11:34:39-04:00

A poster will be presented in person at the American Association for Cancer Research (AACR)...

Precision Biologics Announces Publication Of First-In-Human Phase 1 Clinical Trial With NEO-201

Strattmont Group2023-04-06T13:03:10-04:00

Precision Biologics, Inc. publishes data and analysis from recent First-In-Human Phase 1 Clinical Trial With...

Dr. Philip M. Arlen gives keynote address on NEO-201 Developments at World Antibody Congress, San Diego, CA, March 20th, 2023

Strattmont Group2023-03-16T12:46:14-04:00

Dr. Philip M. Arlen, President and CEO, Precision Biologics, gives keynote address entitled “Preclinical/Clinical Development...

SITC 2022 – Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022

Strattmont Group2022-11-09T11:50:08-05:00

Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...